Table 3.
Comparative effectiveness of liraglutide in patients with T2DM
| References | N | Follow-up (months) | Population | Study design | Treatment | Baseline HbA1c, mean% | Mean change in HbA1c from baseline,% | % patients achieving HbA1c <7% | Baseline weight, mean kg | Mean change in weight from baseline, kg |
|---|---|---|---|---|---|---|---|---|---|---|
| DeKoven et al. 2014 [50] | 234 | 6 | T2DM | Retrospective cohort | Liraglutide | 7.8% | −1.0% | 64.5% | NA | NA |
| 182 | Exenatide | 7.8% | −0.7% | 54.40% | NA | NA | ||||
| Ohki et al. 2012 [40] | 26 | 18 | T2DM with NAFLD | Retrospective cohort | Liraglutide | 8.4% | −0.8% | NA | 81.8 kg | −3.8 kg |
| 36 | Sitagliptin | 8.4% | −1.1% | NA | 81.1 kg | −0.4 kg | ||||
| 20 | Pioglitazone | 7.7% | −0.8% | NA | 78.6 kg | 3.2 kg | ||||
| Nyeland et al. 2015 [58] | 287 | 6 | T2DM | Retrospective database | Liraglutide | 8.8% | −0.9% | 29.3% | 114.3 kg | −3.78 kg |
| 2781 | Sitagliptin | 8.6% | −0.6%a | 22.8% | 95.4 kg | −1.12 kgb | ||||
| Evans et al. 2014 [33] |
256 148 |
12 | T2DM | Retrospective cohort | Liraglutide | 9.6% | −1.23% | NA | 109.7 kg | −3.9 kg |
| Exenatide | 9.8% | −0.79%c | NA | 110.6 kg | −2.9 kg | |||||
| DPP-4i | 8.1% | −0.72%c | NA | 88.9 kg | −0.8 kgc | |||||
| Evans et al. 2013 [32] | 256 | 12 | T2DM | Retrospective chart audit | Liraglutide | 9.8% | −1.28% | NA | 109.7 kg | −3.3 kg |
| 710 | DPP-4i | 8.1% | −0.7%c | NA | 88.9 kg | −0.7 kgc | ||||
| 148 | Exenatide | 9.6% | −0.7%c | NA | 110.6 kg | −2.5 kg | ||||
| 54 | DPP-4i to liraglutide | NR | −0.9%c | NA | NR | −2.5 kg | ||||
| NA | Exenatide to liraglutide | NR | −0.8% | NA | NR | −2.1 kg | ||||
| Chiefari et al. 2015 [30] | 76 | 18 | T2DM | Retrospective cohort | Liraglutide | 8.1% | −1.4% | 51.3% | 73.5 kg | −4.00 kg |
| 103 | Glimepiride | 8.0% | −0.4%b | 11.6%b | 75 kg | no changeb | ||||
| Li et al. 2012 [56] | 376 | 6 | T2DM | Retrospective cohort | Liraglutide | 7.9% | −0.95% | 52% | NA | NA |
| 1089 | Sitagliptin | 8.8% | −0.7%a | 44%a | NA | NA | ||||
| Thomsen et al. 2015 [45] | 298 | 36 | T2DM | Retrospective database | Liraglutide | 7.9% | −1.3% | NA | NA | NA |
| 31 | Exenatide | NR | NR | NA | NA | NA | ||||
| 282 | Other GLD | 7.9% | −0.9% | NA | NA | NA | ||||
| 1262 | DPP-4i | 7.6% | −0.8% | NA | NA | NA | ||||
| 2484 | SU | 8.0% | −1.2% | NA | NA | NA |
DPP-4i dipeptidyl peptidase-4 inhibitor, GLD glucose-lowering drug, HbA1c glycated hemoglobin, NA not available, NAFLD non-alcoholic fatty liver disease, N number of patients, NR not reported, SU sulfonylurea, T2DM type 2 diabetes mellitus
P values for liraglutide vs. active comparator: a P < 0.01; b P < 0.001; c P < 0.05